Back to results
US 10,301,600 B2Granted
Virus strains
AssigneeBiovex Limited
InventorRobert S. Coffin
Life of this patent
Estimating the term…
Abstract
The present invention relates to non-laboratory virus strains, for example of herpes viruses such as HSV, with improved oncolytic and/or gene delivery capabilities as compared to laboratory virus strains.
Claims9
An oncolytic herpes simplex virus 1 (HSV1) strain, wherein said HSV1 strain:
- does not contain a functional ICP 34.5-encoding gene;
- does not contain a functional ICP 47-encoding gene;
- does not contain a heterologous lacZ gene;
- and
- has a greater ability to replicate in or kill tumor cells than HSV1 strain 17+, wherein said HSV1 strain 17+ is modified to lack a functional ICP 34.5-encoding gene.
2 more elements
An oncolytic herpes simplex virus 1 (HSV1) strain, wherein said oncolytic HSV1 strain:
- does not contain a functional ICP 34.5-encoding gene;
- does not contain a heterologous lacZ gene;
- comprises a heterologous gene encoding human GM-CSF, wherein said gene is under the control of a promoter, and wherein said promoter is a ubiquitous promoter or a viral promoter;
- and
- has a greater ability to replicate in or kill tumor cells than HSV1 strain 17+, wherein said HSV1 strain 17+ is modified to lack a functional ICP 34.5-encoding gene.
2 more elements
A pharmaceutical composition comprising:
- an oncolytic herpes simplex virus 1 (HSV1) strain, wherein said HSV1 strain:
- does not contain a functional ICP 34.5-encoding gene;
- does not contain a functional ICP 47-encoding gene;
- does not contain a heterologous lacZ gene, and
- has a greater ability to replicate in or kill tumor cells than HSV1 strain 17+, wherein said HSV1 strain 17+ is modified to lack a functional ICP 34.5-encoding gene;
- and
- a pharmaceutically acceptable carrier or diluent.
4 more elements
A pharmaceutical composition comprising:
- an oncolytic herpes simplex virus 1 (HSV1) strain, wherein said HSV1 strain:
- does not contain a functional ICP 34.5-encoding gene;
- does not contain a heterologous lacZ gene;
- comprises a heterologous gene encoding human GM-CSF, wherein said gene is under the control of a promoter, and wherein said promoter is a ubiquitous promoter or a viral promoter;
- and
- has a greater ability to replicate in or kill tumor cells than HSV1 strain 17+, wherein said HSV1 strain 17+ is modified to lack a functional ICP 34.5-encoding gene.
3 more elements
Dependencies are inferred from the claim text.